Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-(3-(8-cyano–4–(phenylamino)pyrazolo[1,5-a][1,3,5]triazin–2–ylamino)phenyl)acetamide is a synthetic small molecule belonging to the acetanilides class. It is primarily characterized as a potent and selective inhibitor of casein kinase II subunit alpha (CK2α), an enzyme involved in various cellular processes including cell growth and survival. The compound has been studied experimentally for its binding affinity to CK2α with a reported Ki value of 0.35 nM. There are no approved therapeutic indications or marketed formulations; it remains an experimental research tool for probing CK2 biology and potential anti-neoplastic activity in preclinical settings.[2][4]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-(3-(8-cyano-4-(phenylamino)pyrazolo[1,5-a][1,3,5]triazin-2-ylamino)phenyl)acetamide.